Press Releases Dr. Reddy's Laboratories Limited

Equities

500124

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:47 20/05/2026 pm IST			5-day change	1st Jan Change
1,321.90 ^INR	-0.90%		+4.08%	+4.00%

05:13pm	Dr Reddy's launches oral semaglutide biosimilar Obeda in India	RE
16/05	Dr. Reddy?S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada	CI

Press Releases

16/05	Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada	BU
13/05	Doctor Reddy's: Fiscal Q4 Earnings Snapshot	AQ
12/05	Dr Reddy Laboratories : . Reddy’s Q4 & Full Year FY26 Financial Results	PU
29/04	Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada	BU
29/04	Dr Reddy Laboratories : Announces Health Canada Approval for Generic Semaglutide Injection in Canada	PU
23/02	Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	AQ
20/02	Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	BU
19/02	Dr Reddy Laboratories : . Reddy’s forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India	PU
06/02	Dr Reddy Laboratories : Landscape Analysis on Alternatives to Animal Testing for Drug Development in India	PU
29/01	Dr Reddy Laboratories : Corporate Governance Report	PU
21/01	Dr Reddy Laboratories : IFRS Consolidated Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Standalone Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Consolidated Q3 FY 2025-26	PU
21/01	Doctor Reddy's: Fiscal Q3 Earnings Snapshot	AQ
21/01	Dr Reddy Laboratories : . Reddy’s Q3 & 9MFY26 Financial Results	PU
15/01	Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.	AQ
14/01	Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	BU
14/01	Dr Reddy Laboratories : . Reddy’s announces the first-to-market launch of Olopatadine Hyochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	PU
06/01	Dr Reddy Laboratories : . Reddy's launches Hevaxin®, a novel recombinant Hepatitis E vaccine in India	PU
02/12	Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies	BU
02/12	Dr Reddy Laboratories : PBS listing for Zytorvi®* (toripalimab), the first and only immunotherapy for a rare type of head and neck cancer	PU
24/11	Dr Reddy Laboratories : . Reddy’s receives European Commission Approval for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®	PU
30/25/30	Dr Reddy Laboratories : CORPORATE GOVERNANCE REPORT	PU
25/25/25	Dr Reddy Laboratories : INDAS Consolidated Q2 FY 2025-26	PU
25/25/25	Dr Reddy Laboratories : INDAS Standalone Q2 FY 2025-26	PU